Literature DB >> 15516959

Antitumour effects of antiretroviral therapy.

Paolo Monini1, Cecilia Sgadari, Elena Toschi, Giovanni Barillari, Barbara Ensoli.   

Abstract

Infection by human immunodeficiency virus (HIV) is associated with an increased risk of certain tumours, particularly Kaposi's sarcoma, non-Hodgkin's lymphomas and cervical cancer. However, the incidence of these tumours in HIV-infected patients has decreased significantly since the widespread use of highly active antiretroviral therapy (HAART). This effect cannot be solely explained by the ability of these drugs to suppress HIV replication and thereby reconstitute the immune system. Recent studies have shown that inhibitors of the HIV aspartyl protease, which are widely used in HAART, have direct anti-angiogenic and antitumour effects that are unrelated to their antiviral activity. So these drugs might be used to treat cancer in patients who are not infected with HIV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516959     DOI: 10.1038/nrc1479

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  33 in total

1.  Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana.

Authors:  Tanja Mesti; Tanja Južnič Setina; Marjeta Vovk; Barbara Jezeršek Novaković
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

3.  The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

Authors:  Camille Bono; Lionel Karlin; Stephanie Harel; Enguerran Mouly; Sylvaine Labaume; Lionel Galicier; Sébastien Apcher; Hélène Sauvageon; Jean-Paul Fermand; Jean-Christophe Bories; Bertrand Arnulf
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

4.  Repositioning HIV protease inhibitors as cancer therapeutics.

Authors:  Wendy B Bernstein; Phillip A Dennis
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

5.  Therapeutics in renal disease: the road ahead for antiproliferative targets.

Authors:  Peter J Nelson; Stuart J Shankland
Journal:  Nephron Exp Nephrol       Date:  2005-12-07

6.  Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.

Authors:  Mahlon D Johnson; Mary O'Connell; Webster Pilcher
Journal:  J Neurooncol       Date:  2010-07-02       Impact factor: 4.130

7.  Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.

Authors:  Marc A Kowalkowski; Jennifer R Kramer; Peter R Richardson; Insia Suteria; Elizabeth Y Chiao
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

8.  A case of HIV-associated lymphoproliferative disease that was successfully treated with highly active antiretroviral therapy.

Authors:  Haruyuki Fujita; Momoko Nishikori; Akifumi Takaori-Kondo; Noriyoshi Yoshinaga; Yoshiaki Ohara; Takayuki Ishikawa; Hironori Haga; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

Review 9.  Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment.

Authors:  Soren Gantt; Corey Casper
Journal:  Curr Opin Infect Dis       Date:  2011-08       Impact factor: 4.915

10.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.

Authors:  Lara F Bratcher; Vikrant V Sahasrabuddhe
Journal:  Infect Agent Cancer       Date:  2010-05-12       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.